CRISPR Therapeutics co-founder uncloaks an off-the-shelf cell therapy startup with $87M and a lot of fanfare
When Chad Cowan was recruited to Harvard University 20 years ago to work on human embryonic stem cells, he was inspired by the idea that these specialized cells could be used to make insulin-producing beta cells and potentially cure Type 1 diabetes.
However, he soon realized if those cells were going to do it, they would need to overcome the immune response that the body naturally mounts against foreign bodies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.